GlassScriptPhysician profile
Albert L Klaski
NPI 1619132792
$1,557.99
in general payments reported to CMS, 2019-2025
24 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $18.49 · 2021: $29.10 · 2022: $146 · 2023: $35.96 · 2024: $45.22 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $239.86 | 2025 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $231.12 | 2019 | |
| Boston Scientific Corporation | $164.59 | 2020-2022 | |
| Ucb, INC. | $162.30 | 2019 | |
| Abbvie INC. | $153.73 | 2025 | |
| Abbott Laboratories | $132.23 | 2021-2025 | Infinity, Octrode |
| Biogen, INC. | $109.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.22 | 2019 | |
| Amneal Pharmaceuticals LLC | $41.96 | 2019 | |
| Jazz Pharmaceuticals INC. | $27.86 | 2019 | |
| Grifols USA, LLC | $27.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.68 | 2019 | |
| Amgen INC. | $23.38 | 2019 | |
| Promius Pharma LLC | $23.34 | 2019 | |
| Lundbeck LLC | $20.64 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $19.31 | 2019 | |
| Vanda Pharmaceuticals INC. | $15.44 | 2019 | |
| Medtronic USA, INC. | $15.39 | 2019 | |
| W. L. Gore & Associates, INC. | $15.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.07 | 2019 | |
| Genentech USA, INC. | $12.68 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.02 | 2019 | |
| Upsher-Smith Laboratories LLC | $11.56 | 2019 | |
| Lilly USA, LLC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Klaski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.